Conference abstract · 26 Oct 2015
Conference abstractPublished 30 Aug 2022
U.S. Biosimilars Market - A Deep Dive
Associate Director, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Ever since the approval of the first biosimilar drug in the U.S. in 2015, 31 biosimilars have been approved till date (as of September 2021). While 2019 witnessed a steep surge in the approval rates of biosimilars, the COVID-19 pandemic and the resulting lockdown did slow down the approval rates over the last one year (2020 âÂ?Â? 2021). Nevertheless, the U.S. biosimilars market is poised to witness a significant growth of 25% (CAGR) over the next seven years (2021 âÂ?Â? 2028) propelled by the patent expiry of key blockbuster drugs, increased cost-saving initiatives and conducive regulatory framework established by the U.S. government, strategic partnerships, and industry consolidation in addition to the rising incidence of chronic diseases and aging baby-boomer population. Both the biotech firms as well as regulatory authorities have emerged resilient and geared well to a post-pandemic world. This market research service analyses the revenue prospects of the U.S. biosimilars market (in terms of market size, growth rates, YOY revenue forecasts, etc.), patent cliff (biologic drugs due to lose patent protection), key therapeutic areas overview, competitive landscape, key strategic alliances, regulatory framework, pricing and reimbursement policies as well as impact mapping of patients, physicians and payers. Furthermore, strategic recommendations for the success of market participants have also been discussed.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 26 Oct 2015
The economic viability of a U.S. biosimilars industry
Article · 2 Sep 2026
Bridging Sleep and Psychosis: A Deep Dive into the Overlap of Obstructive Sleep Apnea and Schizophrenia
Opinion · 29 Sep 2025
Mathematics Unifying Statistical Mechanics: A Deep Dive
Short communication · 29 Aug 2025
Molecular Mechanisms Of Cellular Life: A Deep Dive
More from this journal
The newest in Journal of Cancer Diagnosis.
Editorial · 1 Dec 2025
Prostate Cancer Screening: Beyond PSA, Toward Precision
Editorial · 1 Dec 2025
Gynecological Screening: Evolving Guidelines, Technology, Challenges
Editorial · 1 Dec 2025
Advancing Early Cancer Detection: Precision & Equity
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Cancer Diagnosis
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Aiswariya Chidambaram”
